亚太地区伤寒疫苗市场预测至 2027 年 - Covid-17 影响及按疫苗类型（减毒活疫苗、荚膜多糖疫苗、结合疫苗等）、给药途径（口服和注射）和国家/地区进行的区域分析
No. of Pages: 90 | Report Code: TIPRE00016285 | Category: Life Sciences
No. of Pages: 90 | Report Code: TIPRE00016285 | Category: Life Sciences
页数：168
伤寒是一种由伤寒沙门氏菌通过摄入受污染的食物和水引起的传染病。这种严重疾病的特征是长期发烧、头痛、恶心、食欲不振、便秘或有时腹泻。伤寒威胁的增加和耐药性威胁的增加帮助伤寒疫苗扩大了市场，特别是在医疗服务、基础设施和发展可能缓慢的农村和难以到达的社区。
亚太地区伤寒发烧疫苗市场预计将从 2019 年的 6475 万美元增至 2027 年的 1.3579 亿美元。预计 2020 年至 2027 年该市场的复合年增长率为 10.0%。亚洲伤寒流行率上升和伤寒免疫计划等因素是促进市场增长的关键因素。另一方面，由于与伤寒疫苗相关的风险，市场可能会产生负面影响。
根据疫苗类型，伤寒疫苗市场可分为减毒活疫苗、荚膜多糖疫苗、结合疫苗等。荚膜多糖疫苗细分市场在 2019 年占据最大市场份额，而减毒活疫苗细分市场预计在预测期内将实现最高的复合年增长率。伤寒疫苗市场根据给药途径分为口服和注射。注射剂细分市场在 2019 年占据最大市场份额，而口服细分市场预计在预测期内复合年增长率最高
报告中包含的亚太伤寒疫苗市场的一些主要二手来源是：印度医学科学研究所、新孟买市政公司、国际贸易管理局、世界卫生组织、中国外文局等。
亚太伤寒疫苗市场 –
按疫苗类型
按给药途径
< p>按国家/地区
Strategic insights for Asia Pacific Typhoid Fever Vaccines involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 64.75 Million |
| Market Size by 2027 | US$ US$ 135.79 Million |
| Global CAGR (2020 - 2027) | 10.0% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 疫苗类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Typhoid Fever Vaccines refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Typhoid Fever Vaccines Market is valued at US$ 64.75 Million in 2019, it is projected to reach US$ US$ 135.79 Million by 2027.
As per our report Asia Pacific Typhoid Fever Vaccines Market, the market size is valued at US$ 64.75 Million in 2019, projecting it to reach US$ US$ 135.79 Million by 2027. This translates to a CAGR of approximately 10.0% during the forecast period.
The Asia Pacific Typhoid Fever Vaccines Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Typhoid Fever Vaccines Market report:
The Asia Pacific Typhoid Fever Vaccines Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Typhoid Fever Vaccines Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Typhoid Fever Vaccines Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Typhoid Fever Vaccines Market
